María José Méndez-Vidal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani et al. · Annals of Oncology · 2017 · 269 citations · Full text

Medicine, Oncology, Pharmacology +17

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer et al. · The Lancet Oncology · 2023 · 163 citations · Full text

Medicine, Oncology, Pharmacology +10

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Thomas Powles, Alejo Rodríguez‐Vida, Ignacio Durán et al. · Journal of Clinical Oncology · 2018 · 90 citations

Medicine, Pharmacology, Surgery +14

A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).

Thomas Powles, James Larkin, Poulam M. Patel et al. · Journal of Clinical Oncology · 2019 · 50 citations

Medicine, Oncology, Pharmacology +14